# Editorial: The immune response to therapeutic antibodies

**Authors:** Michael G. Tovey, Arno J. Kromminga, Daniel T. Mytych

PMC · DOI: 10.3389/fimmu.2025.1554297 · Frontiers in Immunology · 2025-02-10

## Full-text entities

- **Genes:** PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** ADAs (MESH:D016736), DM (MESH:D009223), ADA (MESH:C531816), -resistant prostate cancer (MESH:D011471), Crohn's disease (MESH:D003424)
- **Chemicals:** Remicade (MESH:D000069285)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11848674/full.md

---
Source: https://tomesphere.com/paper/PMC11848674